John Liddle

USPTO Granted Patents = 30 (Patent Applications = 9)

CIPO Patents = 5 (Patent Applications = 2)

EPO Patents = 10 (Patent Applications = 12)

Average Co-Inventor Count = 3.5

ph-index = 4

Forward Citations = 56(Granted Patents)

Location History:

Harlow, GB (2006 - 2007)
Stevenage, GB (2007 - 2022)

Company Filing History:

Glaxosmithkline Intellectual Property Development Limited

patents

4 out of 2,198

Smithkline Beecham Corporation

patents

4. 2 out of 168

The University of Edinburgh

Years Active: 2006-2025

Loading Chart...

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12459906 - 3-(5-chloro-2-oxobenzo[d]oxazol-3(2H)-yl) propanoic acid derivatives as KMO inhibitors (2025-11-04),

2. 11352334 - 3-(5-chloro-2-oxobenzo[d]oxazol-3(2H)-yl) propanoic acid derivatives as KMO inhibitors (2022-06-07),

3. 10815218 - Benzoimidazole derivatives as PAD4 inhibitors (2020-10-27),

4. 10611756 - Method of treating pancreatitis using 1,4-benzoxazine derivatives (2020-04-07),

5. 10407407 - Benzoimidazole derivatives as PAD4 inhibitors (2019-09-10),

6. 10273232 - 3-(6-alkoxy-5-chlorobenzo[D]isoxazol-3-YL)propanoic acid useful as kynurenine monooxygenase inhibitors (2019-04-30),

7. 10246447 - 3-(6-chloro-3-oxo-3,4-dihydro-(2H)-1,4-benzoxazin-4-yl) propanoic acid derivatives and their use as KMO inhibitors (2019-04-02),

8. 10039755 - 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors (2018-08-07),

9. 9932328 - 3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)propanoic acid useful as kynurenine monooxygenase inhibitors (2018-04-03),

10. 9833449 - 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors (2017-12-05),

11. 9518054 - 2-(azaindol-2-yl) benz imidazoles as PAD4 inhibitors (2016-12-13),

12. 9452169 - Substituted diketopiperazines and their use as oxytocin antagonists (2016-09-27),

13. 9447074 - Compounds (2016-09-20),

14. 9408851 - Compounds (2016-08-09),

15. 9127003 - 2-(azaindol-2-yl)benzimidazoles as PAD4 inhibitors (2015-09-08),

Title: John Liddle: Innovator and Patentee in Pharmaceutical Advancements

Introduction

John Liddle, based in Stevenage, GB, is a prolific inventor with a remarkable portfolio of 29 patents to his name. His work primarily focuses on the development of innovative pharmaceutical compounds that address a wide range of medical conditions. Liddle's contributions to the field reflect both his expertise and dedication to advancing healthcare through science.

Latest Patents

Among John Liddle's latest innovations are two notable patents. The first is for "3-(5-chloro-2-oxobenzo[d]oxazol-3(2H)-yl) propanoic acid derivatives as KMO inhibitors," which presents a compound applicable in treating various disorders mediated by KMO, including acute pancreatitis, chronic kidney disease, Alzheimer's disease, and numerous other serious health conditions. The second patent involves "Benzoimidazole derivatives as PAD4 inhibitors," offering compounds that may aid in the treatment of ailments like rheumatoid arthritis, systemic lupus erythematosus, and even several types of cancer.

Career Highlights

John Liddle has made significant strides in the pharmaceutical industry, having worked for well-known companies such as Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited. His tenure at these organizations provided him with vital experience in fostering innovation and protecting intellectual property, allowing him to contribute effectively to the healthcare landscape.

Collaborations

Throughout his career, Liddle has collaborated with esteemed professionals in his field, including coworkers Ann Louise Walker and Deirdre Mary Bernadette Hickey. These collaborations have undoubtedly enriched his work and have led to groundbreaking advancements in the pharmaceuticals he is involved in.

Conclusion

John Liddle's dedication to innovation in pharmaceuticals is evident through his extensive patent portfolio and collaborative endeavors. With a focus on developing treatments for complex medical conditions, he continues to play a vital role in improving healthcare outcomes. His work not only exemplifies the spirit of invention but also highlights the importance of collaboration in advancing medical science.

This text is generated by artificial intelligence and may not be accurate.